Skip to content

ImmunityBio, Inc. IBRX Lease Liability Payments - 2021

Lease Liability Payments - 2021 at other companies

Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s lease liability payments - 2021.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s lease liability payments - 2021?
ImmunityBio, Inc. (IBRX) reported lease liability payments - 2021 of $79K in Q1 2026.
What does lease liability payments - 2021 mean?
This metric captures the total contractual cash payments due for operating and finance leases specifically during the 2021 fiscal period. It serves as a historical or forward-looking benchmark for lease-related cash outflows. It is used by analysts to model the company's fixed cost structure and cash flow requirements.